Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
$0.82
+6.5%
$3.08
$3.25
$17.50
$635K1.091,859 shs3.07 million shs
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$4.67
-2.6%
$5.98
$3.55
$100.80
$6.71M0.65280,849 shs16,403 shs
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
$5.99
+0.3%
$6.90
$2.10
$23.01
$6.28M0.23988,189 shs7,884 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.67
+1.2%
$3.20
$1.75
$9.00
$6.01M1.331.27 million shs31,000 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
0.00%-30.10%-35.26%-46.13%+117.20%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
+9.86%+10.88%-10.47%-32.06%-81.29%
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
+4.37%+1.53%-1.00%-23.85%+57.11%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-1.63%+13.13%+17.53%+57.39%+805.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
2.5969 of 5 stars
3.52.00.00.02.73.30.0
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
0.5166 of 5 stars
0.02.00.00.03.31.70.0
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.7259 of 5 stars
0.05.00.00.02.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
0.00
N/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
3.00
Buy$35.00650.27% Upside
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BCTXF, PRTG, HCWB, and SNOA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$120.00 ➝ $35.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/A($4.55) per shareN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$1.45M4.65N/AN/A($6.08) per share-0.77
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
N/AN/A$8.55 per share0.70$3.74 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.42N/AN/A$2.73 per share1.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
-$3.68M-$3.84N/AN/AN/AN/A-786.77%N/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-$30.02M-$23.25N/AN/A-1,712.94%N/A-90.09%8/13/2025 (Estimated)
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
-$75.34M-$41.65N/AN/AN/AN/AN/A8/26/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.10N/AN/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)

Latest BCTXF, PRTG, HCWB, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
5/15/2025Q1 2025
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A-$0.05N/A-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/AN/AN/AN/AN/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/A
0.07
0.07
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A
0.07
0.07
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38

Institutional Ownership

CompanyInstitutional Ownership
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
2.96%
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
13.36%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
42.70%
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
42.07%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
8772,000N/ANot Optionable
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
401.44 million825,000Not Optionable
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
61.05 million608,000Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.58 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)

New MarketBeat Followers Over Time

Media Sentiment Over Time

BriaCell Therapeutics stock logo

BriaCell Therapeutics OTCMKTS:BCTXF

$0.82 +0.05 (+6.49%)
As of 07/16/2025

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

HCW Biologics stock logo

HCW Biologics NASDAQ:HCWB

$4.66 -0.13 (-2.61%)
As of 01:20 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Portage Biotech stock logo

Portage Biotech NASDAQ:PRTG

$5.98 +0.02 (+0.25%)
As of 01:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.66 +0.05 (+1.24%)
As of 01:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.